Marker in Prostate Cancer Fails to Predict Response to PARP Inhibition
This video examines clinical and genomics data from the NCI 9012 trial, which studied abiraterone combined with a PARP inhibitor in patients with metastatic castration-resistant prostate cancer.
In this video, Maha H. Hussain, MD, of the Lurie Cancer Center in Chicago, discusses clinical and genomics data from the NCI 9012 trial, which studied abiraterone and prednisone with or without the PARP inhibitor veliparib in patients with metastatic castration-resistant prostate cancer (mCRPC).
Hussain reports that ETS fusion–positive tumors did not predict response to treatment, but also that the design of the trial allowed investigators to discover a surprise finding among patients with DNA repair gene–deficient tumors.
The study results were presented (abstract 5001) at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2–6 in Chicago.
![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.")
